Oragenics, Inc. (OGEN) announced on Monday that James Kelly, a Neurologist, has been appointed as its chief medical officer.
Kelly will be responsible for supervising the upcoming Phase II clinical trial of the company's primary drug candidate ONP-002.
Before this role, Kelly was the executive director of the Marcus Institute for Brain Health and a Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado.
For comments and feedback contact: editorial@rttnews.com
Business News